Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Cogent Biosciences Inc’s stock clocked out at $7.62, up 1.74% from its previous closing price of $7.49. In other words, the price has increased by $1.74 from its previous closing price. On the day, 2.13 million shares were traded.
Ratios:
To gain a deeper understanding of COGT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.13 and its Current Ratio is at 5.13. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $17.
Robert W. Baird Downgraded its Outperform to Neutral on February 26, 2024, whereas the target price for the stock was revised from $14 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 14 ’25 when Pinnow Cole bought 43,750 shares for $7.60 per share. The transaction valued at 332,412 led to the insider holds 45,848 shares of the business.
Stock Price History:
Over the past 52 weeks, COGT has reached a high of $12.61, while it has fallen to a 52-week low of $3.72. The 50-Day Moving Average of the stock is 44.07%, while the 200-Day Moving Average is calculated to be -6.59%.
Shares Statistics:
A total of 113.86M shares are outstanding, with a floating share count of 94.03M. Insiders hold about 17.41% of the company’s shares, while institutions hold 100.06% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 10.0 analysts. The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.31 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$1.49 and -$2.63 for the fiscal current year, implying an average EPS of -$2.19. EPS for the following year is -$1.83, with 10.0 analysts recommending between -$1.13 and -$2.9.
